CN113892645A - Composition for protecting heart and application thereof - Google Patents
Composition for protecting heart and application thereof Download PDFInfo
- Publication number
- CN113892645A CN113892645A CN202111183414.9A CN202111183414A CN113892645A CN 113892645 A CN113892645 A CN 113892645A CN 202111183414 A CN202111183414 A CN 202111183414A CN 113892645 A CN113892645 A CN 113892645A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- extract
- heart
- protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 210000002216 heart Anatomy 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 93
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 84
- 240000005662 Aronia melanocarpa Species 0.000 claims abstract description 57
- 235000007425 Aronia melanocarpa Nutrition 0.000 claims abstract description 57
- 240000000249 Morus alba Species 0.000 claims abstract description 50
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 50
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 42
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000008187 granular material Substances 0.000 claims description 34
- 240000006053 Garcinia mangostana Species 0.000 claims description 29
- 235000017048 Garcinia mangostana Nutrition 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
- 239000008101 lactose Substances 0.000 claims description 23
- 229920000858 Cyclodextrin Polymers 0.000 claims description 22
- 239000001116 FEMA 4028 Substances 0.000 claims description 20
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 20
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 20
- 229960004853 betadex Drugs 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000005550 wet granulation Methods 0.000 claims description 8
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 abstract description 12
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 12
- 230000000747 cardiac effect Effects 0.000 abstract description 6
- 206010049565 Muscle fatigue Diseases 0.000 abstract description 3
- 208000000112 Myalgia Diseases 0.000 abstract description 2
- 208000015001 muscle soreness Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 238000004806 packaging method and process Methods 0.000 description 12
- 230000001603 reducing effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000013399 edible fruits Nutrition 0.000 description 11
- 206010063837 Reperfusion injury Diseases 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920002477 rna polymer Polymers 0.000 description 7
- 238000007873 sieving Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- -1 5-phosphoribosyl Chemical group 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102000005747 Transcription Factor RelA Human genes 0.000 description 5
- 108010031154 Transcription Factor RelA Proteins 0.000 description 5
- 230000005189 cardiac health Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091030084 RNA-OUT Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000003953 Solanum lycopersicum var cerasiforme Nutrition 0.000 description 1
- 240000003040 Solanum lycopersicum var. cerasiforme Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
Abstract
The invention discloses a composition for protecting heart and application thereof. The composition comprises D-ribose, aronia melanocarpa extract and mulberry extract. The composition provided by the invention can provide cardiac power, improve myocardial ischemia and protect myocardial cells. Meanwhile, the muscle fatigue can be improved, and the muscle soreness after exercise can be relieved.
Description
Technical Field
The invention relates to the technical field of health food or medicine processing, in particular to a composition for protecting heart and application thereof.
Background
With the progress of society and the rapid development of the modern people, the living rhythm of modern people is accelerated, the problems of various aspects of living pressure and the like are caused, and sub-health symptoms such as low resistance, easy cold, insomnia and dreaminess, early climacteric and the like appear in many middle-aged and elderly people. With the improvement of living standard, modern diseases such as hypertension, hyperlipemia and the like are easy to cause diseases in middle-aged and elderly people. The long-term sub-health state, hypertension, hyperlipemia, heart and other diseases can cause substantial changes, which leads to the pathological changes of the functions of human organs, and even various cardiovascular and cerebrovascular diseases can actively entangle. If the disease is late when the disease is brought, if a healthy drink can be provided for people in daily life, the healthy drink can be eaten when people eat and drink water, the taste can be satisfied, the immunity of the human body can be enhanced, and the heart can be protected to a certain extent. The purpose of prolonging the life is achieved, and the life-prolonging pillow is a very expected thing for people at present.
Disclosure of Invention
In view of the above problems, the present invention provides a composition for protecting heart, which has a synergistic effect through reasonable compatibility, while ensuring the original effect.
The specific technical scheme of the invention is as follows:
1. a composition for protecting the heart, the composition comprising D-ribose, aronia melanocarpa extract, and mulberry extract.
2. The composition of claim 1, wherein the composition further comprises a mangosteen extract and a phytosterol.
3. The composition according to claim 1 or 2, wherein the D-ribose is 5 to 20 parts, the aronia melanocarpa extract is 1 to 5 parts, the mulberry extract is 0.2 to 5 parts, the mangosteen extract is 0 to 5 parts, and the phytosterol is 0 to 1 part by weight;
preferably, the D-ribose accounts for 8-17 parts, the aronia melanocarpa extract accounts for 1-3 parts, the mulberry extract accounts for 0.5-3 parts, the mangosteen extract accounts for 0.3-2 parts, and the phytosterol accounts for 0.1-0.5 part;
more preferably, the content of D-ribose is 10-14 parts, the content of aronia melanocarpa extract is 1-2 parts, the content of mulberry extract is 1-2 parts, the content of mangosteen extract is 0.5-1 part, and the content of phytosterol is 0.1-0.2 part.
4. The composition according to any one of claims 1 to 3, wherein the composition further comprises an adjuvant, preferably, the adjuvant is one or more selected from sorbitol, xylitol, lactose, maltodextrin, beta-cyclodextrin and alpha-cyclodextrin.
5. A formulation for protecting the heart, wherein the formulation is made from a feedstock comprising the composition of any one of claims 1-4.
6. The preparation of claim 5, wherein the preparation is in the form of powder, granules, liquid, tablets or capsules.
7. A method of preparing granules for protecting the heart comprising the steps of:
mixing the composition of any one of claims 1-4 to obtain a mixture;
granulating and finishing the mixture, and then subpackaging to obtain the compound feed.
8. The method of claim 7, wherein the granulating is performed by dry granulation or wet granulation.
9. The process according to claim 7 or 8, wherein the particle size after finishing is 20-40 mesh.
10. The process according to claim 8, wherein, when wet granulation is used, the granules are dried to a moisture content of not more than 8.0 wt%.
11. Use of a composition according to any one of claims 1 to 4 in the field of medicaments or food for protecting the heart.
12. Use of the formulation of claim 5 or 6 in the field of pharmaceuticals or food for protecting the heart.
13. A pharmaceutical composition comprising the composition of any one of claims 1-4 or the formulation of claim 5 or 6.
14. The pharmaceutical composition of claim 13, further comprising a pharmaceutically acceptable excipient.
15. A food composition comprising the composition of any one of claims 1-4 or the formulation of claim 5 or 6.
16. The food composition of claim 15, further comprising a food-acceptable adjuvant.
17. A method of preparing a powder for protecting the heart comprising the steps of:
mixing the composition of any one of claims 1-4.
18. A method of preparing a tablet for protecting the heart comprising the steps of:
the granules prepared by the method of claims 7-10 are tabletted by adding a lubricant.
19. A method of preparing a capsule for protecting the heart comprising the steps of:
adding glidant into granules prepared by the method of claims 7-10, and filling the granules into capsules.
ADVANTAGEOUS EFFECTS OF INVENTION
The composition provided by the invention can provide cardiac power, improve myocardial ischemia and protect myocardial cells. Meanwhile, the muscle fatigue can be improved, and the muscle soreness after exercise can be relieved.
Detailed Description
The present invention will be described in detail below. While specific embodiments of the invention have been shown, it should be understood that the invention may be embodied in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. As one skilled in the art will appreciate, various names may be used to refer to a component. This specification and claims do not intend to distinguish between components that differ in name but not function. In the following description and in the claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description which follows is a preferred embodiment of the invention, however, the description is given for the purpose of illustrating the general principles of the invention and not for the purpose of limiting the scope of the invention. The scope of the present invention is defined by the appended claims.
The invention provides a composition for protecting heart, which comprises D-ribose, aronia melanocarpa extract and mulberry extract.
D-ribose is an important constituent of genetic material-ribonucleic acid (RNA) in organisms, is in a pivot position in the metabolism of nucleoside substances, proteins and fat, and has important physiological functions and wide application prospects. D-ribose, a natural component present in all cells in the organism, is closely related to the formation of adenosine and the regeneration of Adenosine Triphosphate (ATP), and is one of the most basic energy sources for life metabolism. Plays a key role in the metabolism of heart and collateral muscles and can promote the recovery of ischemic tissues and hypoxic tissues.
D-ribose is an important component of RNA (ribonucleic acid) which is a genetic material in an organism, is in a junction position in the organism and has important physiological functions. As an important component of all cells in the body, there is an important relationship with the production of adenosine triphosphate, which is a basic energy source for life activities. Because the human heart and skeletal muscle are slow in synthesizing adenosine triphosphate by themselves, D-ribose can promote the synthesis of adenosine triphosphate in the heart and skeletal muscle. Thereby ensuring that the function of the myocardial cells tends to be normal, obviously improving the heart and simultaneously protecting the arrhythmia caused by the heart ischemia.
Sugar, fat, protein, as tri-potent nutrients in the human body, all synthesize adenosine triphosphate in cells. Sugar is a main substance for synthesizing adenosine triphosphate by human body, and through a series of chemical reactions, glucose can firstly generate 5-phosphoribosyl, then purine nucleotide and finally generate the adenosine triphosphate to generate energy for organisms, but the reaction speed is slow and is too complex. Compared with the method using glucose as raw material, the process for generating the 5-phosphoribose by eating the D-ribose is simpler, and the reaction speed is higher. So that one can recover from excessive movement more quickly.
The Aronia melanocarpa fruit is rich in Vc, antioxidant, various vitamins, mineral elements and other substances, and the antioxidant has an anti-aging function. The fruit extract has good therapeutic effect on radiation disease and heavy metal poisoning, and the fruit also contains specific compounds for treating cancer and heart disease. The fruit of the black chokeberry also has good treatment effect on heart diseases, hypertension and other cardiovascular and cerebrovascular diseases by extracts from the fruit, and the black chokeberry has the following effects: 1. controlling blood sugar: the aronia melanocarpa can control blood sugar and avoid hyperglycemia. The fructose contained in the aronia melanocarpa can be directly digested and absorbed by human bodies, and does not need to depend on insulin metabolism. 2. And (3) reducing blood fat: the Aronia melanocarpa can also reduce blood lipid, and vitamins, amino acids, etc. contained in the Aronia melanocarpa have the effects of softening blood vessel and removing fat on blood vessel wall. 3. Protecting eyesight: the anthocyanin and the lutein contained in the aronia melanocarpa have great effects on protecting eyesight and preventing myopia. 4. Protecting the liver: the nutrient components in the black chokeberry can promote liver metabolism, and if people like to eat greasy food or have a habit of drinking at ordinary times, the eating of the black chokeberry can prevent the occurrence of alcoholic liver and fatty liver. 5. And (3) reducing blood pressure: the aronia melanocarpa has the functions of controlling blood pressure and softening blood vessels, and is very suitable for people with hypertension. 6. Anti-aging: the aronia melanocarpa contains rich anthocyanin, has an anti-oxidation effect, and also has an anti-aging effect after being frequently eaten. 7. Weight losing and slimming: the amino acid in the aronia melanocarpa can inhibit the decomposition and absorption of fat, so that the fat is directly discharged out of the body, and the aronia melanocarpa also has good weight-losing and slimming effects. 8. Preventing senile dementia: the aronia melanocarpa contains rich dietary fiber, has the effect of softening blood vessels, and can keep the activity of brain cells, thereby preventing the occurrence of senile dementia. 9. Protecting intestines and stomach: the common eating of aronia melanocarpa can also protect intestines and stomach, and the contained nutrients can promote the peristalsis of the intestines and stomach and prevent various intestinal tract diseases. 10. Supplementing nutrition: the aronia melanocarpa contains rich nutrition, such as protein, vitamins, various trace elements and the like, and can supplement nutrition for human bodies after being eaten frequently.
Preferably, the preparation of the aronia melanocarpa extract comprises the following steps: taking Aronia melanocarpa, adding 20 times of water, extracting at 60-80 deg.C for 1.5-2h, concentrating under reduced pressure or nano-filtering, adding 5-10 parts of maltodextrin, and spray drying.
The Mori fructus is fruit of Morus alba L of Moraceae. Also named mulberry, sugarcane, mulberry, jujube, mulberry bulb, mulberry. As early as two thousand years ago, mulberry is a tonic for the imperial emperor of China. The mulberry is also called as folk cherry tomato because the mulberry has the characteristics of natural growth and no pollution due to the special growth environment of the mulberry. Modern researches prove that mulberry fruits contain rich active proteins, vitamins, amino acids, carotene, mineral substances, resveratrol, anthocyanin and other ingredients, the nutrition of the mulberry fruits is 5-6 times that of apples and 4 times that of grapes, and the mulberry fruits have various effects and are praised as the best health-care fruits in the 21 st century by the medical community. According to the traditional Chinese medicine, the mulberry has the effects of tonifying liver and kidney, nourishing yin and blood and calming endogenous wind, and is mainly used for treating palpitation and insomnia, dizziness, tinnitus, constipation and night sweat, scrofula, joint disorder and the like. The mulberry can obviously improve the immunity of human bodies after being eaten frequently, and has the effects of delaying senility, improving eyesight, maintaining beauty and keeping young. Modern researches show that the mulberry contains rich fatty acid, which has the effects of decomposing fat, reducing blood fat, preventing angiosclerosis and the like.
Preferably, the preparation of the mulberry extract comprises the following steps: adding 20 times of water into fresh purple mulberry, extracting at 60-80 ℃ for 1.5-2h, concentrating under reduced pressure or nano-filtering, adding 5-10 parts of maltodextrin, and spray drying to obtain the product.
In one embodiment, the composition further comprises a mangosteen extract and a phytosterol.
Preferably, the preparation of the mangosteen extract comprises the following steps: adding 20 times of water into fresh mangosteen mesocarp, extracting at 60-80 deg.C for 1.5-2 hr, concentrating under reduced pressure or nano-filtering, adding 5-10 parts of maltodextrin, and spray drying.
The phytosterol is a sterol substance with similar structure and biochemical characteristics to cholesterol, the 'lipoid' is widely existed in roots, stems, leaves and fruits of plants and cannot be synthesized in human bodies, the only way is through dietary intake, and the phytosterol is widely applied to medicine, industry, daily chemicals and agriculture.
In one embodiment, the weight parts of the D-ribose are 5-20 parts, the aronia melanocarpa extract is 1-5 parts, the mulberry extract is 0.2-5 parts, the mangosteen extract is 0-5 parts, and the phytosterol is 0-1 part;
preferably, the D-ribose accounts for 8-17 parts, the aronia melanocarpa extract accounts for 1-3 parts, the mulberry extract accounts for 0.5-3 parts, the mangosteen extract accounts for 0.3-2 parts, and the phytosterol accounts for 0.1-0.5 part;
more preferably, the content of D-ribose is 10-14 parts, the content of aronia melanocarpa extract is 1-2 parts, the content of mulberry extract is 1-2 parts, the content of mangosteen extract is 0.5-1 part, and the content of phytosterol is 0.1-0.2 part.
For example, the D-ribose can be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, etc. in parts by weight;
the aronia melanocarpa extract can be 1 part, 2 parts, 3 parts, 4 parts, 5 parts and the like;
the mulberry extract can be 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, 2 parts, 3 parts, 4 parts, 5 parts and the like;
the mangosteen extract can be 0, 1, 2, 3, 4, 5, etc.;
the phytosterol may be 0, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, etc.
In one embodiment, when 5 to 20 parts by weight of D-ribose is added, 1 to 5 parts by weight of aronia melanocarpa extract, 0.2 to 5 parts by weight of mulberry extract, 0 to 5 parts by weight of mangosteen extract, and 0 to 1 part by weight of phytosterol are added.
In one embodiment, the composition consists of D-ribose, aronia melanocarpa extract, mulberry extract, mangosteen extract, and phytosterols.
In one embodiment, the composition further comprises an adjuvant, preferably, the adjuvant is one or more selected from the group consisting of sorbitol, xylitol, lactose, maltodextrin, beta-cyclodextrin and alpha-cyclodextrin.
The amount of the auxiliary materials is not limited in the present invention, and can be selected by those skilled in the art as required.
The composition has the effects of improving cardiac activity, improving myocardial ischemia and protecting myocardial cells.
The invention provides a preparation for protecting heart, which is prepared from raw materials containing the composition.
In one embodiment, the formulation is in the form of a powder, granule, liquid, tablet or capsule.
The invention provides a preparation method of granules for protecting heart, which comprises the following steps:
mixing the composition to obtain a mixture;
granulating and finishing the mixture, and then subpackaging to obtain the compound feed.
The ingredients of the composition are pulverized, sieved through a 80-100 mesh sieve, and then mixed to obtain a mixture.
Preferably, the mixture is obtained after 30min of mixing.
The screen is a standard screen.
In the preparation process, auxiliary materials are required to be added to obtain granules, such as the auxiliary materials described above.
In one embodiment, the granulation is a dry granulation or a wet granulation.
In one embodiment, the particle size after finishing is 20-40 mesh.
In one embodiment, where wet granulation is employed, the granules are dried to a moisture content of no more than 8.0 wt%, preferably the drying temperature is 50-70 ℃.
The invention provides the application of the composition or the preparation in the field of medicines or foods for protecting the heart.
The invention provides a pharmaceutical composition, which comprises the composition or the preparation.
In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
The pharmaceutically acceptable excipients are well known to those skilled in the art and can be selected as desired by those skilled in the art, for example, lactose, dextrin, cyclodextrin, maltodextrin, starch, pregelatinized starch, sucrose, isomalt, and the like.
The invention provides a food composition, which comprises the composition or the preparation.
In one embodiment, the food composition further comprises a food acceptable adjuvant.
The food acceptable auxiliary materials are well known to those skilled in the art, and can be selected by those skilled in the art according to needs, for example, the auxiliary materials can be lactose, dextrin, cyclodextrin, maltodextrin, starch, sucrose, isomalt, etc.
The composition has certain effect of reducing the expression of NF-kappa B p65 protein and MPO protein, and shows that the composition has the effect of reducing myocardial ischemia-reperfusion injury.
The composition has the effect of reducing blood fat, and is further beneficial to heart health.
The invention provides a preparation method of powder for protecting heart, which comprises the following steps:
mixing the composition to obtain the product.
The composition can be used for preparing powder with or without auxiliary materials.
The adjuvant may be, for example, lactose, maltodextrin, dextrin, pregelatinized starch, or other acceptable adjuvants
The invention provides a preparation method for preparing a tablet for protecting heart, which comprises the following steps:
adding lubricant into the obtained granules, and tabletting.
The lubricant is a lubricant known in the art and may be, for example, magnesium stearate, colloidal silica, or the like.
The invention provides a preparation method of a capsule for protecting heart, which comprises the following steps:
adding glidant into the granules obtained in the claims 7 to 10, and filling the granules into capsules.
As glidants, those known in the art are mentioned, which may be, for example, talc, aerosil and the like.
The composition comprises D-ribose, the aronia melanocarpa extract and the mulberry extract, and the D-ribose, the aronia melanocarpa extract and the mulberry extract have synergistic effect, so that the expression levels of CINC-1mRNA and NF-kappa B p65 protein are reduced, the curative effect of resisting ischemia-reperfusion injury is improved, and the composition has a strong protective effect on myocardial ischemia-reperfusion injury of rats.
The composition comprises D-ribose, the aronia melanocarpa extract and the mulberry extract, and the three synergistically interact to remarkably reduce the expression of MPO (maximum oxygen production), namely, the composition has the effect of remarkably reducing myocardial ischemia-reperfusion injury.
According to the composition, the D-ribose, the aronia melanocarpa extract and the mulberry extract are synergistically acted, and a small amount of phytosterol is added, so that the composition has a good effect of improving the blood fat level and is beneficial to heart health.
Examples
The invention is described generally and/or specifically for the materials used in the tests and the test methods, in the following examples,% means wt%, i.e. percent by weight, unless otherwise specified. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially, wherein the parts refer to parts by weight, the D-ribose is obtained from Henan Julong biological medicine Co., Ltd, and the aronia melanocarpa and the mulberry are all commercially available products.
Example 1 Effect of phytosterol dosage on product appearance
(1) Pulverizing D-ribose, Aronia melanocarpa extract, Mori fructus extract, Garcinia mangostana extract, phytosterol, beta-cyclodextrin and lactose, sieving with 80-100 mesh standard sieve, mixing according to the dosage shown in Table 1, and mixing for 30min to obtain mixture.
(2) Dry granulating and grading the mixture to obtain granules with a particle size of 20-40 meshes, subpackaging, and packaging into food-grade packaging bags, wherein each bag contains 1.8g of D-ribose, and measuring granule forming rate and dissolubility, wherein the result is shown in Table 1, wherein the granule forming rate is 100% of the weight/total weight of the granules with 20-40 meshes;
solubility: taking 1 bag of single dose packaged granule, adding 50ml of hot water, stirring for 5min, and observing the solution state.
TABLE 1 Studies of phytosterol dosage
As can be seen from the above table, the addition of excessive phytosterol will affect the forming rate and solubility of the product, so the quality control is preferably below 3.8%.
EXAMPLE 2-1 preparation of granules
(1) Crushing D-ribose, aronia melanocarpa extract, mulberry extract, beta-cyclodextrin and lactose, sieving by a standard sieve of 80-100 meshes, mixing the crushed D-ribose 2 parts, aronia melanocarpa extract 1.2 parts, mulberry extract 1 part, mangosteen extract 0.5 part, phytosterol 0.1 part, beta-cyclodextrin 6 parts and lactose 14 parts, and mixing for 30min to obtain a mixture.
(2) And (3) performing dry granulation and size stabilization on the mixture to enable the particle size to be 20-40 meshes, subpackaging, and packaging into food-grade packaging bags with each bag being 3.1 g.
EXAMPLE 2 preparation of granules
(1) Crushing D-ribose, aronia melanocarpa extract, mulberry extract, mangosteen extract, phytosterol, beta-cyclodextrin and lactose, sieving by a standard sieve of 80-100 meshes, mixing the crushed D-ribose 5 parts, aronia melanocarpa extract 1 part, mulberry extract 1 part, mangosteen extract 0.5 part, phytosterol 0.1 part, beta-cyclodextrin 5 parts and lactose 12 parts, and mixing for 30min to obtain a mixture.
(2) And (2) performing wet granulation on the mixture, drying at 50 ℃ until the water content is 7.5%, granulating until the particle size is 20-40 meshes, subpackaging, and packaging into food-grade packaging bags with 3.1g per bag.
Examples 2-3 preparation of granules
(1) Crushing D-ribose, aronia melanocarpa extract, mulberry extract, mangosteen extract, phytosterol, beta-cyclodextrin and lactose, sieving the crushed D-ribose, aronia melanocarpa extract, 1.2 parts of aronia melanocarpa extract, 1 part of mulberry extract, 0.5 part of mangosteen extract, 0.1 part of phytosterol, 4 parts of beta-cyclodextrin and 10 parts of lactose, and mixing the mixture for 30min to obtain a mixture.
(2) And (2) performing wet granulation on the mixture, drying at 50 ℃ until the water content is 7.8%, granulating until the particle size is 20-40 meshes, subpackaging, and packaging into food-grade packaging bags with 3.1g per bag.
Examples 2-4 preparation of granules
(1) Crushing D-ribose, aronia melanocarpa extract, mulberry extract, mangosteen extract, phytosterol, beta-cyclodextrin and lactose, sieving the crushed D-ribose, aronia melanocarpa extract, 1.2 parts of aronia melanocarpa extract, 1 part of mulberry extract, 0.5 part of mangosteen extract, 0.1 part of phytosterol, 4 parts of beta-cyclodextrin and 8 parts of lactose, and mixing the mixture for 30min to obtain a mixture.
(2) And (3) performing dry granulation and size stabilization on the mixture to enable the particle size to be 20-40 meshes, subpackaging, and packaging into food-grade packaging bags with each bag being 3.1 g.
EXAMPLES 2-5 TO EXAMPLE 2-15 preparation of granules
Weighing the corresponding raw materials according to the formula in the table 2, adding a proper amount of beta-cyclodextrin and lactose (the proportion of the beta-cyclodextrin and the lactose is about 5:11), adjusting the parts to 24.8 parts in total, uniformly mixing, granulating and subpackaging. The preparation process was the same as in examples 2-4.
Comparative example 1 preparation of granules
(1) Pulverizing D-ribose, beta-cyclodextrin and lactose, sieving with a standard sieve of 80-100 meshes, mixing the pulverized D-ribose 14 parts, beta-cyclodextrin 3.4 parts and lactose 7.4 parts for 30min to obtain a mixture.
(2) And (3) performing dry granulation and size stabilization on the mixture to enable the particle size to be 20-40 meshes, subpackaging, and packaging into food-grade packaging bags with each bag being 3.1 g.
Comparative example 2 preparation of granules
Weighing the corresponding raw materials according to the formula in the table 2, adding a proper amount of beta-cyclodextrin and lactose (the proportion of the beta-cyclodextrin and the lactose is about 5:11), adjusting the parts to 24.8 parts in total, uniformly mixing, granulating and subpackaging. The preparation process was the same as in examples 2-4.
Comparative examples 3 to 4 preparation of granules
Weighing the corresponding raw materials according to the formula in the table 2, adding a proper amount of beta-cyclodextrin and lactose (the proportion of the beta-cyclodextrin and the lactose is about 5:11), adjusting the parts to 24.8 parts in total, uniformly mixing, granulating and subpackaging. The preparation process was the same as in examples 2-4.
TABLE 2 tables of the respective component ratios in examples 2-1 to 2-15 and comparative examples 1-4
Experimental example 1 comparison of protective effects of different formulations on myocardial ischemia reperfusion injury of rats
Animal models and groups: 126 clean-grade healthy SD male rats of 10 weeks of age, weighing about 250 + -30 g, were randomly divided into a sham-operated group, an ischemia-reperfusion group, example 2-1 to 2-15 groups, and 21 groups of comparative example 1, comparative example 2, comparative example 3 and comparative example 4 before surgery, each group consisting of 6 rats. After anesthesia by intraperitoneal injection, 2% sodium pentobarbital (40mg/kg) is subjected to tracheotomy and then is connected with a small animal respirator (frequency is 80 times/min, respiration ratio is 1: 1, and tidal volume is 18 ml). The skin, muscle and ribs are opened layer by layer at the 2-5 ribs on the left edge of the rat sternum, the heart is exposed, the pericardium is separated, the anterior descending branch of the left coronary artery is found out between the left auricle and the pulmonary artery cone, and a ligature is threaded at the position 0.2cm after the anterior descending branch is started by a 5.0 suture needle with a thread.
The sham operation group: the suture is not tied after threading, and the suture is taken down after 45min, and the thoracic cavity is closed. The next day after surgery, saline was gavaged for 7 consecutive days.
Ischemia reperfusion group: ligating suture, treating cardiac apex pale as myocardial ischemia, cutting suture 45min later to restore perfusion of ischemic coronary artery, and closing thoracic cavity. The next day after surgery, saline was gavaged for 7 consecutive days.
Administration group: ligating suture, treating cardiac apex pale as myocardial ischemia, cutting suture 45min later to restore perfusion of ischemic coronary artery, and closing thoracic cavity. Each group was gavaged the next day after surgery for 7 consecutive days. Each group was administered a dose of 700mg/kg body weight of each group of granules.
Approximately 250mg of myocardial tissue of the free wall of the far-end left ventricle at the ligation site of each experimental group was taken on day 8 and stored in liquid nitrogen at-80 ℃.
Wherein, the expression of the mRNA of the neutrophil chemotactic substance-1 (CINC-1) induced by the cell factors in the myocardial tissues is detected by adopting an RT-PCR method, and the specific operation is as follows: taking 50mg of myocardial tissue, extracting total RNA of myocardial cells according to an animal RNAout instruction manual, measuring the D (260)/D (280) value and the RNA concentration of the total RNA by a Beckman Coulter Du800 instrument, carrying out reverse transcription according to a high-efficiency reverse transcription kit instruction to obtain cDNA, and carrying out PCR amplification by taking the cDNA as a template. The PCR primer sequence and the amplification condition are respectively as follows: the internal reference beta-actin upstream primer sequence is shown as SEQ ID NO. 1, and the nucleotide sequence is as follows: 5'-GAGAGGGAAATCGTGCGTGAC-3', and the sequence of the downstream primer is shown in SEQ ID NO: 2, the nucleotide sequence is as follows: 5'-CATCTGCTGGAAGGTGGACA-3', the annealing temperature is 58 ℃, the cycle is 30 times, and the product length is 452 bp; the sequence of the CINC-1 upstream primer is shown as SEQ ID NO: 3, the nucleotide sequence is as follows: 5'-GGCAGGGATTCACTTCAAGAACA-3', and the sequence of the downstream primer is shown in SEQ ID NO: 4, the nucleotide sequence is as follows: 5'-TTACTTGGGGCACCCTTTAGCA-3', the annealing temperature is 58 ℃, the cycle is 30 times, and the length of the product is 175 bp. The PCR products were subjected to agarose gel electrophoresis, and the results were analyzed using a gel imaging system, and the results are shown in Table 3.
Expression of NF-. kappa. B p65 protein: taking 100mg of myocardial tissue, extracting total protein according to Westem and IP cell lysate instructions, determining protein concentration by a BCA method, carrying out SDS-PAGE gel electrophoresis, transferring to a PVDF membrane by a wet transfer method, sealing for 1h by 5% skimmed milk powder at 37 ℃ after the membrane is washed conventionally, adding rabbit anti-rat NF-kappa B p65 primary antibody (diluted 1: 500) and rabbit anti-rat beta-actin primary antibody (diluted 1: 2000) after the membrane is washed, incubating for overnight at 4 ℃, adding horseradish enzyme labeled goat anti-rabbit secondary antibody (diluted 1: 2000) after the membrane is washed, incubating for 1h at 37 ℃, developing by a chemiluminescence method, and analyzing by a gel imaging analysis system, wherein the results are shown in Table 3.
ELISA for determination of MPO protein amount in myocardial tissue: the MPO protein expression level in myocardial tissue was measured according to the procedures of the MPO ELISA kit manual, and the results are shown in Table 4.
TABLE 3 expression of CINC-1mRNA and NF-. kappa. B p65 protein (x. + -. s, n. RTM.6) between groups
Note: #, P < 0.05, compared with sham operation group; p < 0.05, compared to ischemia-reperfusion group; p < 0.01, compared to ischemia-reperfusion group
As can be seen from Table 3, P of each of the other groups is less than 0.05 compared with that of the sham operation group, which indicates that the modeling is successful, and each of the administration groups shows certain reduction effects on the expression of CINC-1mRNA and NF-kappa B P65 protein compared with that of the ischemia-reperfusion group, which indicates that the efficacy of reducing myocardial ischemia-reperfusion injury is achieved. In addition, as can be seen from comparison of examples 2-1 to 2-7, the expression levels of CINC-1mRNA and NF- κ B p65 protein decreased more significantly than the model group with the increase of the ratio of D-ribose, but the decrease effect did not increase when the amount was increased to a certain amount.
Comparing examples 2-5, 2-3, 2-4, 2-8, and 2-9 with comparative examples 1 and 2, it can be seen that the addition of components such as aronia melanocarpa, mulberry, mangosteen, phytosterol, etc. can achieve a better synergistic effect, and improve the efficacy of resisting ischemia-reperfusion injury.
Comparing examples 2-5 with examples 2-10 and examples 2-11, it can be seen that there is a suitable range for the addition amount of aronia melanocarpa, mulberry, mangosteen and phytosterol, and that too low an addition amount is not effective, but too high an addition amount is not optimal. Particularly, the results of comparing examples 2-5 with examples 2-15, and comparative examples 3 and 4 show that the aronia melanocarpa has a remarkable effect of enhancing D-ribose to improve myocardial ischemia-reperfusion injury, and the mangosteen extract also has a synergistic effect with D-ribose.
TABLE 4 MPO expression in myocardial tissue between groups
Note: #, P < 0.05, compared with sham operation group; p < 0.05, compared to ischemia-reperfusion group; p < 0.01, compared to ischemia-reperfusion group
As can be seen from table 4, P was less than 0.05 in each of the other groups compared with the sham operation group, indicating successful modeling, and each of the administration groups showed a certain effect of reducing MPO expression compared with the ischemia-reperfusion group, indicating that the efficacy of reducing myocardial ischemia-reperfusion injury was exhibited. The overall result shows that the group containing the extracts of the aronia melanocarpa and the mulberry has more remarkable MPO reducing effect.
Comparing examples 2-5, 2-15, comparative example 3, comparative example 4, it can be seen from examples 2-4 that the aronia melanocarpa, mulberry extract and mangosteen extract have a synergistic effect on improving the effect of D-ribose to reduce MPO, especially the aronia melanocarpa extract has the most obvious effect.
Experimental example 2 Effect of different formulations on blood lipid levels in mice
Animals and groups: c57BL/6 mouse, male, weight 18-22 g, (Beijing Wintolite laboratory animals Co.), clean grade. After 1w of adaptive feeding, the mice were randomly divided into a normal control, a high fat control, example 1-prescription 1 group, examples 2-1 to 2-15 groups, comparative example 1 group, comparative example 2 group, comparative example 3 group, and comparative example 4 group for 23 groups, each group consisting of 6 mice. The normal control group is fed with basal feed, the other groups are fed with high-fat feed, and animals in each group freely take food and drink distilled water during the experiment.
Administration: administration groups were intragastrically administered each group of drugs at a dose of 860mg/kg body weight of each group of granules. The normal control group and the high fat control group were given an equal amount of physiological saline solution. Continuously administering 5w of the medicine, killing a mouse (fasting for 12h, free distilled water drinking), removing eyeballs for blood sampling, centrifuging at 3000r/min for 15min, and reserving serum for blood biochemical detection, wherein the detection indexes are as follows: cholesterol (TC), Triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and Free Fatty Acid (FFA) were measured by a fully automatic biochemical analyzer (TBA-2000FR, Toshiba, Japan), and the results are shown in Table 5.
TABLE 5 comparison of blood lipid levels in each group
Note: #, P < 0.05, compared with normal control group; p < 0.05, compared to high fat control group
Because heart health is closely related to blood lipid, the improvement of different formulations on the blood lipid level of high-lipid mice is determined. As can be seen from the table above, different formulations have different degrees of blood lipid reducing effect, and especially the addition of a small amount of phytosterol has a good effect on improving the blood lipid level, thereby being more beneficial to the heart health.
Experimental example 3
Given to 100 persons in sub-health state, the aged 55-65 years old, the blood lipid and blood pressure are in critical states of hyperlipemia and hypertension respectively, and the symptoms are dizziness, arrhythmia, poor sleep and acne pigmentation on face. The solid beverage of the embodiment 2-5 of the invention is taken with 50ml of warm water once in the morning and at night every day. After the food is continuously eaten for two months, the blood pressure and the blood fat are normal, the symptoms of dizziness, arrhythmia, poor sleep and acne pigmentation on the face are all improved, the body is light and full of vitality, the sleep is improved, the heart vitality is enhanced, the face is ruddy and full of youth.
Experimental example 4
100 persons 55-65 years old and 100 persons were randomly divided into two groups, one group was administered with 1 bag of the solid beverage of the group of examples 2-5 and 50ml of warm water, and the other group was administered with 50ml of warm water as a blank group. After taking the medicine, 5km of mountain climbing walking exercise is carried out, and the activity time is 2-2.5 h. Compared with a blank group administration group, the medicine has more vigorous energy and does not have obvious symptoms such as asthma and the like in the activity process. The number of people with leg soreness on the 2 nd and 3 rd days of follow-up visit is only 12%, while the incidence rate of leg soreness in the blank group is as high as 70%, and most people have obvious asthma symptoms in the blank group running process.
In conclusion, the composition provided by the invention can improve the curative effect of resisting ischemia-reperfusion injury, can reduce MPO expression, can reduce blood fat, and is beneficial to heart health.
The composition of the present invention can improve sleep, enhance cardiac activity, and enrich people with young state, and in addition, it can improve muscle fatigue and relieve muscular soreness after exercise.
The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. However, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the protection scope of the technical solution of the present invention.
Sequence listing
<110> Beijing Hezhengdao science and technology Co Ltd
<120> composition for protecting heart and use thereof
<130> PE01636
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 21
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description: artificially synthesized sequences
<400> 1
gagagggaaa tcgtgcgtga c 21
<210> 2
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description: artificially synthesized sequences
<400> 2
catctgctgg aaggtggaca 20
<210> 3
<211> 23
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description: artificially synthesized sequences
<400> 3
ggcagggatt cacttcaaga aca 23
<210> 4
<211> 22
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description: artificially synthesized sequences
<400> 4
ttacttgggg caccctttag ca 22
Claims (14)
1. A composition for protecting the heart, the composition comprising D-ribose, aronia melanocarpa extract, and mulberry extract.
2. The composition of claim 1, wherein the composition further comprises a mangosteen extract and a phytosterol.
3. The composition according to claim 1 or 2, wherein the D-ribose is 5 to 20 parts, the aronia melanocarpa extract is 1 to 5 parts, the mulberry extract is 0.2 to 5 parts, the mangosteen extract is 0 to 5 parts, and the phytosterol is 0 to 1 part by weight;
preferably, the D-ribose accounts for 8-17 parts, the aronia melanocarpa extract accounts for 1-3 parts, the mulberry extract accounts for 0.5-3 parts, the mangosteen extract accounts for 0.3-2 parts, and the phytosterol accounts for 0.1-0.5 part;
more preferably, the content of D-ribose is 10-14 parts, the content of aronia melanocarpa extract is 1-2 parts, the content of mulberry extract is 1-2 parts, the content of mangosteen extract is 0.5-1 part, and the content of phytosterol is 0.1-0.2 part.
4. The composition according to any one of claims 1 to 3, wherein the composition further comprises an adjuvant, preferably, the adjuvant is one or more selected from sorbitol, xylitol, lactose, maltodextrin, beta-cyclodextrin and alpha-cyclodextrin.
5. A formulation for protecting the heart, wherein the formulation is made from a feedstock comprising the composition of any one of claims 1-4;
preferably, the preparation is in the form of powder, granules, liquid, tablets or capsules.
6. A method of preparing granules for protecting the heart comprising the steps of:
mixing the composition of any one of claims 1-4 to obtain a mixture;
granulating and finishing the mixture, and then subpackaging to obtain the compound feed.
7. The method of claim 6, wherein the granulation is dry granulation or wet granulation;
preferably, the particle size of the whole particles is 20-40 meshes;
preferably, when wet granulation is employed, the granules are dried to a moisture content of not more than 8.0 wt%.
8. Use of a composition according to any one of claims 1 to 4 in the field of medicaments or food for protecting the heart.
9. Use of the formulation of claim 5 in the field of pharmaceuticals or food for protecting the heart.
10. A pharmaceutical composition comprising the composition of any one of claims 1-4 or the formulation of claim 5;
preferably, it further comprises pharmaceutically acceptable excipients.
11. A food composition comprising the composition of any one of claims 1-4 or the formulation of claim 5;
it also contains food acceptable adjuvants.
12. A method of preparing a powder for protecting the heart comprising the steps of:
mixing the composition of any one of claims 1-4.
13. A method of preparing a tablet for protecting the heart comprising the steps of:
the granules prepared by the method of claim 6 or 7 are added with a lubricant and tabletted.
14. A method of preparing a capsule for protecting the heart comprising the steps of:
adding glidant into granules prepared by the method of claim 6 or 7, and filling the granules into capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111183414.9A CN113892645A (en) | 2021-10-11 | 2021-10-11 | Composition for protecting heart and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111183414.9A CN113892645A (en) | 2021-10-11 | 2021-10-11 | Composition for protecting heart and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113892645A true CN113892645A (en) | 2022-01-07 |
Family
ID=79191274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111183414.9A Pending CN113892645A (en) | 2021-10-11 | 2021-10-11 | Composition for protecting heart and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113892645A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219183A (en) * | 2006-01-05 | 2008-07-16 | 李平亚 | Application of mangosteen rind extract in preparing medicament for treating myocardial ischemia |
| CN101243810A (en) * | 2008-03-14 | 2008-08-20 | 内蒙古蒙牛乳业（集团）股份有限公司 | Yoghourt redounding to heart health and preparation method |
| CN105535624A (en) * | 2016-01-15 | 2016-05-04 | 中科和素（天津）医药科技有限公司 | Nutrition preparation for relieving cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN109152400A (en) * | 2016-03-07 | 2019-01-04 | 自然阳光生产公司 | Improve the method and composition of weight loss and health of heart in addition to diet and movement |
| CN111657501A (en) * | 2020-05-14 | 2020-09-15 | 中国海洋大学 | Oyster peptide cordyceps sinensis mycelium composition with function of enhancing immunity and application thereof |
-
2021
- 2021-10-11 CN CN202111183414.9A patent/CN113892645A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219183A (en) * | 2006-01-05 | 2008-07-16 | 李平亚 | Application of mangosteen rind extract in preparing medicament for treating myocardial ischemia |
| CN101243810A (en) * | 2008-03-14 | 2008-08-20 | 内蒙古蒙牛乳业（集团）股份有限公司 | Yoghourt redounding to heart health and preparation method |
| CN105535624A (en) * | 2016-01-15 | 2016-05-04 | 中科和素（天津）医药科技有限公司 | Nutrition preparation for relieving cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN109152400A (en) * | 2016-03-07 | 2019-01-04 | 自然阳光生产公司 | Improve the method and composition of weight loss and health of heart in addition to diet and movement |
| CN111657501A (en) * | 2020-05-14 | 2020-09-15 | 中国海洋大学 | Oyster peptide cordyceps sinensis mycelium composition with function of enhancing immunity and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 周叔说生活: "热烈庆祝【长寿俱乐部首款自有产品偳粒美-d核糖专家评审研讨会】顺利召开", pages 2, Retrieved from the Internet <URL:https://www.sohu.com/a/484808884_121124574> * |
| 长寿俱乐部: "疫情下的防疫+防慢病，专家建议这样做", pages 341 - 126, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s?src=11×tamp=1692322321&ver=4719&signature=53OCu*2H7cjL61uxQobWDe1pgVz0XYiHmaYNy7wLu0Z82Uq0cpCBcDP-1Wy86GUrUwLLp9c3dOegqx*sgczG5YxLvqtjgdCCY7-hV*qw8xMubOYegTry-dlbRlo2Gy95&new=1> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102907604B (en) | Health-care product having effects of reducing blood sugar and pressure, losing weight, relaxing bowels, maintaining beauty and resisting fatigue and production process thereof | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN102526698A (en) | Cordyceps polypeptide amino acid nutrient solution | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| JP2018510641A (en) | Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement | |
| US20120171309A1 (en) | Formulations and methods for increasing efficacies and improving flavors of formulations containing gynostemma plant | |
| JP2018070570A (en) | Lindera plant extract | |
| CN112618608A (en) | Composition with function of dispelling effects of alcohol and preparation method and application thereof | |
| WO2022165700A1 (en) | Polypeptide nutrition powder and preparation method therefor | |
| CN102090637A (en) | Collagen-containing compound nutritious powder | |
| KR102444911B1 (en) | Composition for preventing or treating muscle-related diseases, improvement of muscular function or exercise performance comprising an extract of wild edible greens as an active ingredient | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN109645295A (en) | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health | |
| KR20110121246A (en) | Natural functional food for anti-obesity wellbeing diet and its producing method | |
| CN113892645A (en) | Composition for protecting heart and application thereof | |
| JP6541061B2 (en) | Composition for promoting clock gene expression | |
| CN103169742A (en) | Application of elaeagnus conferta roxb | |
| JP6999907B2 (en) | Composition for promoting clock gene expression | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN102499366A (en) | Health-care food for adjusting blood fat and preventing fatigue | |
| CN105597083B (en) | A kind of pair of liver kidney has health food of auxiliary protection function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |